G4.5 Pamam Dendrimer-Risperidone: Biodistribution and Behavioral Changes in In Vivo ModelMaria Jimena Prieto1,2*, Nahuel Eduardo del Rio Zabala1,2, Cristian Hernán Marotta1,2, Dario Bichara3, Sergio Simonetta3, Nadia Silvia Chiaramoni1,2 and Silvia del Valle Alonso1,2
- *Corresponding Author:
- Maria Jimena Prieto
Department of Science and Technology
National University of Quilmes, Argentina
Tel: +54 1143657100, Ext 4323
Fax: +54 1143657132
E-mail: [email protected]
Received date: November 13, 2013; Accepted date: December 18, 2013; Published date: December 20, 2013
Citation: Prieto MJ, del Rio Zabala NE, Marotta CH, Bichara D, Simonetta S, et al. (2013) G4.5 Pamam Dendrimer-Risperidone: Biodistribution and Behavioral Changes in In Vivo Model. J Nanomedine Biotherapeutic Discov 4:121. doi: 10.4172/2155-983X.1000121
Copyright: © 2013 Prieto MJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Dendritic polymers are considered as emerging and outstanding carriers as modern medicinal systems due to their derivatisable branched architecture and possibility to modify them in numerous ways. Here, G4.5 PAMAM dendrimers were obtained as carriers of the antipsychotic drug risperidone. Despite their extensive applicability in the pharmaceutical field, the use of dendrimers as carriers in biological systems is constrained due to their inherent associated toxicity. The biocompatibility of dendrimers and dendrimer-risperidone complexes was evaluated in vivo for biological performance. To this end, the pharmacokinetics and biodistribution after oral treatment of free risperidone and dendrimer-risperidone complexes were studied in healthy mice. Also, the behavioral changes such as locomotion, aggression, dominance in male and female mice were evaluated both after a single dose and after daily therapy for 8 days. Also, in vivo effects of risperidone and dendrimer-risperidone complexes on the locomotion of zebrafish larvae were explored.
The data obtained suggest that the unmetabolized risperidone complexes increase the arrival to the brain after 90 minutes. On the other hand, behavioral studies showed an increase in the potency of the drug in animals treated with the complexes.